Drug used for another disease slows progression of Parkinson's
A drug being evaluated to treat an entirely different disorder helped slow the progression of Parkinson’s disease in mice, a team of researchers has reported. Their study found that the drug, AT2101, which has also been studied for Gaucher disease, improved motor function, stopped inflammation in the brain and reduced levels of alpha-synuclein, a protein critically involved in Parkinson's. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 8, 2014 Category: Science Source Type: news
UCLA researchers find that drug used for another disease slows progression of Parkinson’s
A new study from UCLA found that a drug being evaluated to treat an entirely different disorder helped slow the progression of Parkinson’s disease in mice.
The study, published in the October edition of the journal Neurotherapeutics, found that the drug, AT2101, which has also been studied for Gaucher disease, improved motor function, stopped inflammation in the brain and reduced levels of alpha-synuclein, a protein critically involved in Parkinson’s.
Although the exact cause of Parkinson’s is unknown, evidence points to an accumulation of alpha-synuclein, which has been found to be common to all people with the diso...
Source: UCLA Newsroom: Health Sciences - October 8, 2014 Category: Universities & Medical Training Source Type: news
FDA Clears Taliglucerase Alfa for Kids With Gaucher Disease FDA Clears Taliglucerase Alfa for Kids With Gaucher Disease
Taliglucerase alfa is now indicated for long-term enzyme replacement therapy for children and adults with type 1 Gaucher disease. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 2, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
Pfizer and Protalix’s Elelyso receives FDA approval to treat type 1 Gaucher disease
Pfizer and Protalix BioTherapeutics have secured approval from the US Food and Drug Administration (FDA) for Elelyso (taliglucerase alfa) to treat paediatric patients with type 1 Gaucher disease. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 31, 2014 Category: Pharmaceuticals Source Type: news
New Drug Approved for Gaucher Disease Type 1 (FREE)
By the Editors
The FDA has approved eliglustat (Cerdelga) to treat … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 21, 2014 Category: Primary Care Source Type: news
FDA Clears Eliglustat (Cerdelga) for Gaucher DiseaseFDA Clears Eliglustat (Cerdelga) for Gaucher Disease
The new drug proved as effective as enzyme replacement therapy in treating the rare genetic disease in a clinical trial. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 19, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA approves Sanofi's Gaucher disease drug Cerdelga
(Reuters) - The U.S. Food and Drug Administration said on Tuesday it has approved Sanofi SA's drug Cerdelga to treat patients with type 1 Gaucher disease, a rare genetic disorder. (Source: Reuters: Health)
Source: Reuters: Health - August 19, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
FDA approves new drug to treat a form of Gaucher disease
The U.S. Food and Drug Administration today approved Cerdelga (eliglustat) for the long-term treatment of adult patients with the Type 1 form of Gaucher disease, a rare genetic disorder. (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 19, 2014 Category: American Health Source Type: news
Glucocerebrosidase Is Shaking Up the SynucleinopathiesGlucocerebrosidase Is Shaking Up the Synucleinopathies
Recent progress in unraveling the mechanisms involving the enzyme glucocerebrosidase is not only advancing therapy for Gaucher disease, but may impact understanding of Parkinson's disease as well. Brain (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 25, 2014 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th Meeting
CARMIEL, Israel, June 27, 2014 -- (Healthcare Sales & Marketing Network) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (PLX.TA), announced today that new clinical data on ELELYSOTM (taliglucerase alfa) will be presented at the European Working Group on ... BiopharmaceuticalsProtalix BioTherapeutics, ELELYSO, taliglucerase alfa, Gaucher Disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 27, 2014 Category: Pharmaceuticals Source Type: news
Gaucher Disease Points Way to Possible New Treatment for Parkinson's
Source: Parkinson's Disease Foundation
Related MedlinePlus Pages: Gaucher's Disease, Parkinson's Disease (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - June 26, 2014 Category: Consumer Health News Source Type: news
Protalix starts Phase II trial of oral GCD to treat Gaucher disease
Israel-based Protalix BioTherapeutics has started enrolling patients in its Phase IIa clinical trial of oral glucocerebrosidase (GCD), or oral GCD (PRX-112) for treatment of Gaucher disease. (Source: Drug Development Technology)
Source: Drug Development Technology - June 19, 2014 Category: Pharmaceuticals Source Type: news
A Product For Gaucher Disease And A Plant-Cell For Protein Production – Protalix Biotherapeutics Is On The Rise
Protalix has a unique plant-cell platform for therapeutic protein production and an approved product, Elelyso/Uplyso (taliglucerase alfa), for Gaucher disease. In the company’s pipeline is a chemically modified version of the recombinant alpha-Galactosidase-A protein for Fabry disease (Phase 1/2), an oral glucocerebrosidase (GCD) enzyme replacement therapy for Gaucher disease (Phase 1), an oral anti-TNF (tumor necrosis factor) fusion protein for autoimmune/inflammatory conditions (preclinical), and a human deoxyribonuclease I (DNase I) for cystic fibrosis (preclinical), and other enzyme replacement therapies in early...
Source: Pharmaceutical Online News - May 30, 2014 Category: Pharmaceuticals Source Type: news
Protalix gets marketing approval in Australia for ELELYSO to treat Gaucher disease
Israel-based biopharmaceutical firm Protalix BioTherapeutics has received approval from the Australian Therapeutic Goods Administration (TGA) for ELELYSO (taliglucerase alfa) for injection, as a long-term enzyme replacement therapy for treatment of G… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 22, 2014 Category: Pharmaceuticals Source Type: news
People with Gaucher Disease at Seven to Nine Percent Risk of Developing Parkinson's
Source: Parkinson's Disease Foundation
Related MedlinePlus Pages: Gaucher's Disease, Parkinson's Disease (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 21, 2014 Category: Consumer Health News Source Type: news
